溴隐亭
医学
利培酮
不利影响
中止
催乳素
内科学
多巴胺激动剂
精神分裂症(面向对象编程)
抗精神病药
随机对照试验
安慰剂
药理学
多巴胺能
多巴胺
激素
精神科
替代医学
病理
作者
Haining Yuan,Chuanyue Wang,Stephen Cho Wing Sze,Yao Tong,Qihua Tan,Xiu-Jie Feng,Rui-Mei Liu,Ji-Zhi Zhang,Yanbo Zhang,Zhang‐Jin Zhang
标识
DOI:10.1097/jcp.0b013e318172473c
摘要
Hyperprolactinemia is a common adverse effect that occurs as a result of antipsychotic therapies, which often results in discontinuation. Empirical evidence has shown that some herbal medicines have suppressive effects on prolactin (PRL) hyperactivities. This study was designed to compare the herbal preparation called Peony-Glycyrrhiza Decoction (PGD) with bromocriptine (BMT), a dopamine agonist widely used for PRL-secreting disorders, in the treatment of risperidone-induced hyperprolactinemia. Twenty schizophrenic women who were under risperidone maintenance treatment, diagnosed with hyperprolactinemia (serum PRL levels >50 μg/L), and currently experiencing oligomenorrhea or amenorrhea were selected for the study. Subjects were randomized to additional treatment with PGD (45 g/d) followed by BMT (5 mg/d) or BMT followed by PGD at the same doses for 4 weeks each, with an interval of 4-week washout period between 2 treatment sessions. The severity of psychotic symptoms, adverse events, serum PRL, estradiol, testosterone, and progesterone levels were examined at baseline and end point. Peony-Glycyrrhiza Decoction treatment produced a significant baseline-end point decrease in serum PRL levels, without exacerbating psychosis and changing other hormones, and the decreased amplitudes were similar to those of BMT (24% vs 21%-38%). Moreover, there was a significantly greater proportion of patients during PGD treatment than BMT treatment showing improvements on adverse effects associated with hyperprolactinemia (56% vs 17%, P = 0.037). These results suggest that the herbal therapy can yield additional benefits while having comparable efficacy in treating antipsychotic-induced hyperprolactinemia in individuals with schizophrenia.
科研通智能强力驱动
Strongly Powered by AbleSci AI